Two doses of MMR vaccine--sufficient to eradicate measles, mumps and rubella?
A review has been done of the available literature on measles, mumps, rubella and vaccines against these diseases. So far, 17 studies on the same virus strains as those in M-M-R II have been published. The rate of seroconversion is practically 100% for rubella, generally more than 90% for measles and between 40 and 100% for mumps. Immediate side effects of vaccination are mild in infants and negligible in schoolchildren. However, the follow-up periods are short. In the only 10-year follow-up published, 14 subjects remained at the end of the period, and the vaccine studied differed from M-M-R II. Large, well-documented studies of MMR vaccination in unselected populations are rare. It must be of crucial importance that the immunity situation is followed up continuously for both vaccinated and non-vaccinated individuals when a mass vaccination programme has been introduced as there will be a risk of outbreaks of diseases mostly among young adults.